{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:50:11Z","timestamp":1792799411082,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["MLP145"],"award-info":[{"award-number":["MLP145"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012323","name":"CSIR - Indian Institute of Chemical Biology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001332","name":"Council for Scientific and Industrial Research, South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012339","name":"CSIR \u2013 Indian Institute of Chemical Biology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.vaccine.2025.128147","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T13:01:26Z","timestamp":1766494886000},"page":"128147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Engineered dengue virus NS1 mRNA-lipid nanoparticle induces therapeutic IgG production that lacks autoantibody activity and neutralizes NS1 entry in liver cells"],"prefix":"10.1016","volume":"73","author":[{"given":"Sandeepan","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feroza","family":"Begum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhadip","family":"Ghora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upasana","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.128147_bb0005","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.128147_bb0010","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.mi.44.100190.003245","article-title":"Flavivirus genome organization, expression, and replication","volume":"44","author":"Chambers","year":"1990","journal-title":"Ann Rev Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2025.128147_bb0015","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1128\/CMR.00035-09","article-title":"Dengue virus pathogenesis: an integrated view","volume":"22","author":"Martina","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2025.128147_bb0020","series-title":"Dengue: Guidelines for diagnosis, treatment, prevention and control","author":"World Health Organization","year":"2009"},{"key":"10.1016\/j.vaccine.2025.128147_bb0025","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1016\/j.vaccine.2018.02.062","article-title":"Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines","volume":"36","author":"Vannice","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128147_bb0030","doi-asserted-by":"crossref","first-page":"E8378","DOI":"10.1073\/pnas.1714250115","article-title":"Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials","volume":"115","author":"Juraska","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2025.128147_bb0035","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029371","article-title":"Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? The path to a dengue vaccine: learning from human natural dengue infection studies and vaccine trials","volume":"10","author":"de Silva","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.vaccine.2025.128147_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005584","article-title":"In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination","volume":"11","author":"Whitehead","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2025.128147_bb0045","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/infdis\/jiz081","article-title":"Magnitude and functionality of the NS1-specific antibody response elicited by a live-attenuated tetravalent dengue vaccine candidate","volume":"221","author":"Sharma","year":"2020","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2025.128147_bb0050","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of Dengvaxia\u00ae: development to deployment","volume":"15","author":"Thomas","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"39","key":"10.1016\/j.vaccine.2025.128147_bb0055","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1016\/j.vaccine.2015.08.008","article-title":"Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study","volume":"33","author":"Torresi","year":"2015","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2025.128147_bb0060","first-page":"351","article-title":"Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naive and dengue-exposed individuals","volume":"215","author":"Henein","year":"2017","journal-title":"J Infect Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2025.128147_bb0065","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2025.128147_bb0070","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"issue":"35","key":"10.1016\/j.vaccine.2025.128147_bb0075","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1016\/j.vaccine.2020.06.079","article-title":"Ethics of a partially effective dengue vaccine: lessons from the Philippines","volume":"38","author":"Halstead","year":"2020","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.vaccine.2025.128147_bb0080","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1016\/j.vaccine.2015.06.067","article-title":"Preclinical development of a dengue tetravalent recombinant subunit vaccine: immunogenicity and protective efficacy in nonhuman primates","volume":"33","author":"Govindarajan","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128147_bb0085","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3389\/fimmu.2020.01252","article-title":"Anti-dengue vaccines: from development to clinical trials","volume":"11","author":"Pinheiro-Michelsen","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.128147_bb0090","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0042-6822(88)90408-4","article-title":"Evidence that the mature form of the flavivirus nonstructural protein NS1 is a dimer","volume":"162","author":"Winkler","year":"1988","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2025.128147_bb0095","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1128\/JVI.73.7.6104-6110.1999","article-title":"Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent fashion","volume":"73","author":"Flamand","year":"1999","journal-title":"J Virol"},{"issue":"Pt 3","key":"10.1016\/j.vaccine.2025.128147_bb0100","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1099\/0022-1317-68-3-853","article-title":"Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1","volume":"68","author":"Schlesinger","year":"1987","journal-title":"J Gen Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2025.128147_bb0105","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.vaccine.2011.12.034","article-title":"Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant","volume":"30","author":"Amorim","year":"2012","journal-title":"Vaccine"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2025.128147_bb0110","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1016\/S0264-410X(03)00310-4","article-title":"Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice","volume":"21","author":"Wu","year":"2003","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.vaccine.2025.128147_bb0115","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1016\/j.vaccine.2005.08.022","article-title":"DNA vaccine against the non-structural 1 protein (NS1) of dengue 2 virus","volume":"24","author":"Costa","year":"2006","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128147_bb0120","doi-asserted-by":"crossref","first-page":"12933","DOI":"10.1038\/s41598-020-69515-9","article-title":"Peptides targeting dengue viral nonstructural protein 1 inhibit dengue virus production","volume":"10","author":"Songprakhon","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128147_bb0125","doi-asserted-by":"crossref","first-page":"6975","DOI":"10.1038\/s41598-017-07308-3","article-title":"Antibodies against modified NS1 wing domain peptide protect against dengue virus infection","volume":"7","author":"Lai","year":"2017","journal-title":"Sci Rep"},{"issue":"Pt 8","key":"10.1016\/j.vaccine.2025.128147_bb0130","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1099\/0022-1317-69-8-2101","article-title":"Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus","volume":"69","author":"Henchal","year":"1988","journal-title":"J Gen Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128147_bb0135","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/jmv.10261","article-title":"Antibodies from dengue patient sera cross-react with endothelial cells and induce damage","volume":"69","author":"Lin","year":"2003","journal-title":"J Med Virol"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2025.128147_bb0140","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/BF01309478","article-title":"Precise location of sequential dengue virus subcomplex and complex B cell epitopes on the nonstructural-1 glycoprotein","volume":"137","author":"Falconar","year":"1994","journal-title":"Arch Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2025.128147_bb0145","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s007050050127","article-title":"The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin\/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis","volume":"142","author":"Falconar","year":"1997","journal-title":"Arch Virol"},{"issue":"11","key":"10.1016\/j.vaccine.2025.128147_bb0150","doi-asserted-by":"crossref","first-page":"9726","DOI":"10.1074\/jbc.M110.170993","article-title":"Molecular mimicry of human endothelial cell antigen by autoantibodies to nonstructural protein 1 of dengue virus","volume":"286","author":"Liu","year":"2011","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.vaccine.2025.128147_bb0155","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4049\/jimmunol.169.2.657","article-title":"Endothelial cell apoptosis induced by antibodies against dengue virus nonstructural protein 1 via production of nitric oxide","volume":"169","author":"Lin","year":"2002","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2025.128147_bb0160","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01418-24","article-title":"Dengue virus NS1 leads to downregulation of HNF4 alpha in liver cells resulting in a decrease in coagulation factors I, V, X, and XIII, contributing to coagulopathy","volume":"98","author":"Das","year":"2024","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25014458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25014458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:02:33Z","timestamp":1770282153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25014458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":32,"alternative-id":["S0264410X25014458"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128147","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineered dengue virus NS1 mRNA-lipid nanoparticle induces therapeutic IgG production that lacks autoantibody activity and neutralizes NS1 entry in liver cells","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128147"}}